Nivolumab in pre-treated malignant pleural mesothelioma: real-world data from the Dutch expanded access program.

ABSTRACT:

Background

Randomized phase III trials are ongoing to investigate the efficacy of nivolumab in malignant pleural mesothelioma (MPM), but real-world data are still scarce. In this real-world study, we investigated the clinical outcomes of nivolumab treatment in pre-treated MPM patients.

Methods

Data from 107 nivolumab treated MPM patients within the Dutch expanded access program were retrospectively analyzed. Treatment was independent of programmed death ligand 1 (PD-L1) expression on tumor samples. Univariable and multivariable analyses were performed to evaluate the relationship between clinically important factors, baseline peripheral blood parameters and survival. The landmark method was used to compare the outcome of patients according to their radiological response.

SUBMITTER: Cantini L 

PROVIDER: S-EPMC7481613 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature